Department of Emergency
Medicine and Surgery, Centre Hospitalo-Universitaire Pitié-Salpêtrière,
Assistance-Publique Hôpitaux de Paris (AP-HP), 47-83 boulevard de
l’hôpital, 75013 Paris, Université Pierre et Marie Curie Paris 6, France.
Abstract HTML Views: 125 PDF Downloads: 30 Total Views/Downloads: 155
Abstract HTML Views: 104 PDF Downloads: 24 Total Views/Downloads: 128
Congestive heart failure (CHF) is the main cause of acute dyspnea and acute respiratory failure in elderly patients
(> 65 years) presented to an emergency department (ED), and it is associated with high morbidity and mortality. Btype
natriuretic peptide (BNP) is a polypeptide, released by ventricular myocytes directly proportional to wall tension, for
lowering renin-angiotensin-aldosterone activation. For diagnosing CHF, both BNP and its biologically inactive N terminal
fragment (NT-proBNP) have similar accuracy, even in the oldest (> 85 years). Threshold values are higher in elderly
population. Studies demonstrated that the use of BNP or NT-proBNP in dyspneic patients early in the ED reduced the
time to discharge and total treatment cost. BNP and NT-proBNP should be available in every ED 24 hours a day, because
literature strongly suggests the beneficial impact of an early appropriate diagnosis and treatment in elderly dyspneic patients.
The purpose of this article is to review their impact on clinical use in the emergency setting for elderly patients admitted